Drug intelligence / Profile preview

D085

Development stage: Unknown
Lead developer: Chong Kun Dang Pharmaceutical
Modality: Small Molecules
Administration: Oral

Overview

D085 is referenced as a drug intervention in clinical trials, specifically in combination with CKD-330 and CKD-333 for the evaluation of safety and pharmacokinetic characteristics in healthy volunteers. The available information does not specify its active ingredient, mechanism of action, or therapeutic class. It appears to be an investigational product used by Chong Kun Dang Pharmaceutical in clinical research related to cardiovascular diseases[5][3]. No further details about its chemical identity or pharmacological properties are provided in public sources.

Other names: D085D-085D 085

Beyond the preview

Go deeper on D085.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on D085.

Explore the full profile